UNSPSC 51283724: Cefuroxime axetil

This classification denotes a cephalosporin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z49QDT0J8Z. European Medicines Agency schedules Cefuroxime axetil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01139MIG. Cefuroxime axetil generally arises in the molecular formula C20H22N4O10S. The term 'cefuroxime axetil' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule cefuroxime axetil under HS 29419000 and SITC 54139.

As of Q4 2014, CEFUROXIME AXETIL remains US FDA's Preferred Term for this commodity. Cefuroxime axetil bears US NLM identifiers UMLS ID C0055015 and NCI Concept Code C28918. SMILES: CC(OC(=O)C)OC(=O)C1=C(CS[C@H]2N1C(=O)[C@H]2NC(=O)/C(=N\OC)/C3CCCO3)COC(=O)N.

UNSPSC 51283724 Cefuroxime axetil is a Commodity code that, based on recent state and local solicitations, does not align with the work actually being procured under this designation. The code nominally identifies a specific antibiotic pharmaceutical product, yet the recent opportunities posted against it span naloxone procurement, direct-to-manufacturer pharmacy initiatives, broad medical and first aid supplies for emergency response, and multi-source generic pharmaceuticals and OTC products through a cooperative purchasing vehicle. None of these solicitations specifically target cefuroxime axetil or reference this individual drug product in their scope.

The mismatch between the code's nominal scope and the actual work being solicited suggests either inconsistent UNSPSC coding by issuing bodies or tagging errors in the opportunity data. Issuers include Seminole County (Florida), the Texas Health and Human Services Commission, the City of Tampa, and the Minnesota Multistate Cooperative Purchasing Alliance administering multi-state agreements. The geographic spread spans Florida, Texas, and Minnesota, with opportunities ranging from emergency management naloxone and drug deactivation systems to fire department medical supplies and statewide pharmaceutical contracting. Recent activity includes an IFB from Seminole County (due July 26, 2023, for naloxone and deactivation systems), an RFI from Texas HHS (April 3, 2026, for direct-to-manufacturer pharmacy programs), an IFB from Tampa (due March 13, 2026, for medical and first aid supplies with an estimated $700,000 contract value), and an RFP from MMCAP (due March 26, 2026, for generic pharmaceuticals and OTC products across participating jurisdictions). The code shows little relevant recent activity for cefuroxime axetil specifically and should not be relied upon for procurement strategy targeting that pharmaceutical product.